Replicate Bioscience raises $40m to develop its self-replicating RNA (srRNA)

ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune and inflammatory disorders and other diseases, using self-replicating RNA (srRNA). Replicate will use $40 million in committed Series A funding from ATP to advance multiple novel srRNA programs into clinical development.

Replicate Bioscience raises $40m to develop its self-replicating RNA (srRNA)
self-replicating RNA

“Next-generation srRNA agents are taking RNA therapeutics into many more areas of disease treatment, and what Replicate is doing to define and expand this field is completely new and exciting,” said Michael Ehlers, M.D., Ph.D., Chief Scientific Officer of ATP and a venture partner at the firm. “ATP is investing in Replicate because we see the company’s technology as a quantum leap in RNA therapeutics.”

Self-replicating RNAs, or srRNAs, work by copying themselves inside cells of the body and instructing the cells to make, and keep making, therapeutic proteins. Replicate uses synthetic biology, original molecular design principles, and a diverse, proprietary repertoire of virally derived vectors to engineer custom srRNAs that offer unique advantages compared to other RNA or srRNA therapeutic approaches. These advantages include lower dosing levels by several orders of magnitude; increased duration of therapeutic effect; and selectively programmed ability to either activate or evade the immune system.

Nathaniel Wang, Ph.D., Replicate Bioscience Chief Executive Officer, said: “We started Replicate to build a best-in-class srRNA platform from scratch—to pursue our vision of a better way to make srRNAs that we are convinced can solve life-threatening medical problems, from drug resistance in cancer to autoimmune and inflammatory disorders and more. We are thrilled to partner with ATP, to accelerate our progress towards realizing that vision for patients.”


Healthcare Investors Database